Literature DB >> 28237208

The Fiscal Consequences Attributed to Changes in Morbidity and Mortality Linked to Investments in Health Care: A Government Perspective Analytic Framework.

Mark P Connolly1, Nikolaos Kotsopoulos2, Maarten J Postma3, Aomesh Bhatt4.   

Abstract

Governments have an enormous economic and political stake in the health of their populations. Population health is not only fundamental to economic growth but also affects short-term and long-term government expenditure on health care, disability, and other social programs and influences direct and indirect tax receipts. Fiscal transfers between citizen and state are mostly ignored in conventional welfare economics analyses based on the hypothesis that there are no winners or losers through transference of wealth. However, from the government perspective, this position is flawed, as disability costs and lost taxes attributed to poor health and reduced productive output represent real costs that pose budgetary and growth implications. To address the value of health and health care investments for government, we have developed a fiscal health analytic framework that captures how changes in morbidity and mortality influence tax revenue and transfer costs (e.g., disability, allowances, ongoing health costs). The framework can be used to evaluate the marginal impact of discrete investments or a mix of interventions in health care to inform governmental budgetary consequences. In this context, the framework can be considered as a fiscal budget impact and/or cost-benefit analysis model that accounts for how morbidity and mortality linked to specific programs represent both ongoing costs and tax revenue for government. Mathematical models identical to those used in cost-effectiveness analyses can be employed in fiscal analysis to reflect how disease progression influences public accounts (e.g., tax revenue and transfers).
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Keywords:  fiscal; health; public economics; public finance; welfare economics

Mesh:

Year:  2017        PMID: 28237208     DOI: 10.1016/j.jval.2016.11.018

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  10 in total

1.  Disparities in Access to Musculoskeletal Care: Narrowing the Gap: AOA Critical Issues Symposium.

Authors:  Dane H Salazar; Christopher J Dy; W Stephen Choate; Howard M Place
Journal:  J Bone Joint Surg Am       Date:  2019-11-20       Impact factor: 5.284

Review 2.  Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project.

Authors:  Debbie Van Baarle; Kaatje Bollaerts; Giuseppe Del Giudice; Stephen Lockhart; Christine Luxemburger; Maarten J Postma; Aura Timen; Baudouin Standaert
Journal:  Vaccine       Date:  2020-07-24       Impact factor: 3.641

3.  Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.

Authors:  Mark P Connolly; Saswat Panda; Julien Patris; Bouke P C Hazenberg
Journal:  Orphanet J Rare Dis       Date:  2019-09-18       Impact factor: 4.123

Review 4.  How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.

Authors:  Baudouin Standaert; Christophe Sauboin; Rodrigo DeAntonio; Alen Marijam; Jorge Gomez; Lijoy Varghese; Sharon Zhang
Journal:  J Mark Access Health Policy       Date:  2020-01-31

5.  Estimating the government public economic benefits attributed to investing in assisted reproductive technology: a South African case study.

Authors:  Mark P Connolly; Saswat Panda; Gitau Mburu; Thabo Matsaseng; James Kiarie
Journal:  Reprod Biomed Soc Online       Date:  2020-09-04

6.  Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs.

Authors:  Baudouin Standaert; Christophe Sauboin; Quentin J Leclerc; Mark P Connolly
Journal:  Pharmacoeconomics       Date:  2020-11-25       Impact factor: 4.981

7.  Forecasting of Future Medical Care Expenditure in Japan Using a System Dynamics Model.

Authors:  Sachie Inoue; Hua Xu; Jean-Claude Maswana; Makoto Kobayashi
Journal:  Inquiry       Date:  2022 Jan-Dec       Impact factor: 1.730

8.  The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.

Authors:  Nikolaos Kotsopoulos; Mark P Connolly; Michael Willis; Andreas Nilsson; Åsa Ericsson; James Baker-Knight
Journal:  Diabetes Obes Metab       Date:  2022-03-06       Impact factor: 6.408

9.  Estimating the Fiscal Costs of Osteoporosis in Korea Applying a Public Economic Perspective.

Authors:  Mark P Connolly; Saswat Panda; Ha Young Kim
Journal:  J Bone Metab       Date:  2019-11-30

10.  Estimating the broader fiscal consequences of acute hepatic porphyria (AHP) with recurrent attacks in Belgium using a public economic analytic framework.

Authors:  Mark P Connolly; Nikos Kotsopoulos; Sebastian Vermeersch; Julien Patris; David Cassiman
Journal:  Orphanet J Rare Dis       Date:  2021-08-04       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.